Volume 7.00 | Jan 8

Mammary Cell News 7.00 January 8, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
Target Specific Delivery of Anti-Cancer Drug in Silk Fibroin Based 3D Distribution Model of Bone-Breast Cancer Cells
Scientists evaluated the in vitro 3D model of the breast cancer and bone cells to understand the cellular interactions in the presence of a targeted anticancer drug delivery system. Human breast adenocarcinoma and osteoblast like cells were co-cultured to evaluate the efficiency of doxorubicin loaded folic acid conjugated silk fibroin nanoparticle as drug delivery system. [ACS Appl Mater Interfaces] Abstract
MammoCult™: Most Published Mammosphere & Tumorsphere Culture Medium (Commercially Available) FREE Sample Request
PUBLICATIONS (Ranked by impact factor of the journal)

Toca-1 Is Suppressed by p53 to Limit Breast Cancer Cell Invasion and Tumor Metastasis
Researchers observed that breast cancer cell lines with mutant p53 have high levels of Toca-1 compared to those with WT p53. Stabilization of WT p53 led to further reduction in Toca-1 mRNA and protein levels in normal breast epithelial cells and breast cancer cells. [Breast Cancer Res] Abstract | Full Article

MicroRNA-574-3p, Identified by MicroRNA Library-Based Functional Screening, Modulates Tamoxifen Response in Breast Cancer
To identify tamoxifen response-related microRNAs (miRNAs) in breast cancer, MCF-7 cells infected with a lentiviral miRNA library were treated with 4-hydroxytamoxifen or vehicle for four weeks, and the amounts of individual miRNA precursors that had integrated into the genome were evaluated by microarray. [Sci Rep]
Full Article

Disulfiram-Induced Cytotoxicity and Endo-Lysosomal Sequestration of Zinc in Breast Cancer Cells
Few studies have investigated zinc effects on disulfiram action, despite it having high affinity for this metal. Investigators studied the cytotoxic effects of disulfiram in breast cancer cells, and its relationship with both intra and extracellular zinc. [Biochem Pharmacol] Abstract

HET0016, a Selective Inhibitor of 20-HETE Synthesis, Decreases Pro-Angiogenic Factors and Inhibits Growth of Triple Negative Breast Cancer in Mice
A selective inhibitor of 20-HETE synthesis, HET0016, has been reported to inhibit angiogenesis. HET0016 effects were analyzed on MDA-MB-231 derived breast cancer in mouse and in vitro cell line. [PLoS One]
Full Article

Differentially Expressed Proteins in Human MCF-7 Breast Cancer Cells Sensitive and Resistant to Paclitaxel
In order to detect proteins potentially involved in the mechanism of resistance to taxanes, researchers assessed differences in protein expression in MCF-7 breast cancer cells that are sensitive to paclitaxel and in the same cells with acquired resistance to paclitaxel. [Exp Cell Res] Abstract

Caveolin-1 Mediates Inflammatory Breast Cancer Cell Invasion via the Akt1 Pathway and RhoC GTPase
Using a reliable inflammatory breast cancer (IBC) cell line, scientists set out to determine if caveolin-1 expression affects RhoC-mediated IBC invasion. IBC cell invasion is significantly decreased when caveolin-1 is down regulated. [J Cell Biochem] Abstract

Role of EHD2 in Migration and Invasion of Human Breast Cancer Cells
The authors investigated the role of eps15 homology domain-containing 2 (EHD2) in breast cancer migration and invasion by wound healing assay and trans-well invasion assays. Overexpression of EHD2 suppressed, while elimination of EHD2 promoted, the migration and invasion of breast cancer cells. [Tumor Biol] Abstract

Upregulation of Acetylcholinesterase Mediated by p53 Contributes to Cisplatin-Induced Apoptosis in Human Breast Cancer Cell
The regulation of acetylcholinesterase (AChE) expression during apoptosis induced by cisplatin, a current used anticancer drug, was investigated in human breast cancer cell line MCF-7. [J Cancer] Full Article


Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Investigators performed an uncontrolled, single-group, multicenter, investigator-initiated study of adjuvant paclitaxel and trastuzumab in 406 patients with tumors measuring up to 3 cm in greatest dimension. Patients received weekly treatment with paclitaxel and trastuzumab for 12 weeks, followed by nine months of trastuzumab monotherapy. [New Engl J Med] Abstract | Press Release

PIK3CA Mutations Are Associated with Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer
Researchers investigated whether mutations in the gene encoding the phosphatidylinositol 3-kinase catalytic subunit (PIK3CA) correlates with response to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in patients with breast cancer. [J Clin Oncol] Abstract | Press Release | Editorial

Phase II, Multicenter, Open-Label, Randomized Study of YM155 plus Docetaxel as First-Line Treatment in Patients with HER2-Negative Metastatic Breast Cancer
Researchers assessed the efficacy and tolerability of YM155, a survivin suppressor, in combination with docetaxel, compared with docetaxel alone in patients with HER2-negative metastatic breast cancer. [Breast Cancer Res Treat] Full Article

Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
Mammary Lineage Tracing: The Coming of Age
The authors briefly summarize and compare different mammary gland lineage tracing strategies, examine associated caveats and discuss future challenges and opportunities. [Cell Mol Life Sci] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan (IMMU-132) for Triple-Negative Breast Cancer Therapy
Immunomedics, Inc. announced that it has received notice from the U.S. Food and Drug Administration (FDA) designating as a Fast Track development program the investigation of sacituzumab govitecan for the treatment of patients with triple-negative breast cancer who have failed prior therapies for metastatic disease. [Immunomedics, Inc.] Press Release

NYU Langone Medical Center Utilizing New Technology to Detect Lingering Cancer Cells during Breast Surgery
The Division of Breast Surgery at NYU Langone was the first in New York City to utilize MarginProbe® for early stage breast cancer. MarginProbe® utilizes non-destructive radio-frequency spectroscopy technology in the operating room to analyze the outer margins of removed cancerous tissue to detect traces of cancer cells. [NYU Langone Medical Center] Press Release

Novel Anti-Cancer Drug, ONC201, Focus of Alliance between Oncoceutics and MD Anderson
Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center announced the initiation of a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer drug. [The University of Texas MD Anderson Cancer Center] Press Release

Vaxil Receives Approval to Open Additional Clinical Trial Center for Patients with Metastatic Breast Cancer at Kaplan Medical Center, Rehovot
Vaxil Bio reports that it has received approval from Kaplan’s medical center, Rehovot, ethical committee to open up a second center at this hospital for its Phase I/II clinical trial VAXIL-010. [Vaxil Bio Therapeutics Ltd.]
Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cancer 2015
February 6-7, 2015
Kiev, Ukraine

NEW Keystone Symposium 2015 – Endoderm Lineages in Development and Disease
February 8-13, 2015
Keystone, United States

NEW Exploring DNA Repair Pathways as Targets for Cancer Therapy
February 12-15, 2015
Cancun, Mexico

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

NEW Principal Investigator – Human Cancer Genomics and Mouse Modeling (Lunenfeld-Tanenbaum Research Institute)

NEW Lab Manager – Precision Cancer Medicine (Boston University)

NEW Postdoctoral Position – Precision Cancer Medicine (Boston University)

NEW Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Postdoctoral Position – Experimental Breast Cancer Therapy (University of Pennsylvania)

Postdoctoral Position – Breast Cancer Metastasis (Northwestern University)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Media Development (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us